ArticleJournal of clinical microbiology2021
Comparative Performance of Latest-Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease.
Article in Journal of clinical microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Evaluation of Chagas TESA VirClia assay for chronicJournal of clinical microbiology · 2026Article
- A Trypanosoma cruzi trans-sialidase peptide demonstrates high serological prevalence among infected populations across endemic regions.The Journal of clinical investigation · 2026Article
- Chagas disease screening of maternal donors in publicly banked umbilical cord blood in North Carolina, United States 2007-2023.Pregnancy (Hoboken, N.J.) · 2025Article
- Identification of seropositive cases of Chagas disease in pregnant women in a non-endemic risk area of the state of Mexico: The importance of screening prenatal.Parasite epidemiology and control · 2025Article
- Comparison between chimeric Trypanosoma cruzi antigens (ABBOTT PRISM Chagas assay) and local antigenic extracts in blood bank screening for Chagas disease in an endemic area for the Triatoma dimidiata vector.Revista do Instituto de Medicina Tropical de Sao Paulo · 2025Article
- The diagnostic value of two antigenic domains derived from theFrontiers in microbiology · 2025Article
- Identification of highly conservedEmerging microbes & infections · 2024Article
- Diversity of Chagas disease diagnostic antigens: Successes and limitations.PLoS neglected tropical diseases · 2024Review
- Humans seropositive for Trypanosoma cruzi co-infected with intestinal helminths have higher infectiousness, parasitaemia and Th2-type response in the Argentine Chaco.Parasites & vectors · 2024Article
- Retrospect, advances and challenges in Chagas disease diagnosis: a comprehensive review.Lancet regional health. Americas · 2024Review
- Article
- Case Report: A Case of Post-Transplant Chagas Reactivation after Negative Trypanosoma cruzi Testing.The American journal of tropical medicine and hygiene · 2023Article
- Chagas Disease Maternal Seroprevalence and Maternal-Fetal Health Outcomes in a Parturition Cohort in Western El Salvador.Tropical medicine and infectious disease · 2023Article
- The Trypanosoma cruzi Antigen and Epitope Atlas: antibody specificities in Chagas disease patients across the Americas.Nature communications · 2023Article
- Evaluation of InBios Chagas Detect Fast, a Novel Enzyme-Linked Immunosorbent Assay for the Detection of Anti-Trypanosoma cruzi Antibodies.Journal of clinical microbiology · 2023Article
- Proof of Concept of a Novel Multiepitope Recombinant Protein for the Serodiagnosis of Patients with Chagas Disease.Pathogens (Basel, Switzerland) · 2023Article
- Laboratory diagnosis ofFrontiers in parasitology · 2023Review
- Evaluation of the Performance of Ortho T. cruzi ELISA Test System for the Detection of Antibodies to Trypanosoma cruzi.Journal of clinical microbiology · 2022Article
- Gold Nanoshells-Based Lateral Flow Assay for the Detection of Chagas Disease at the Point-of-Care.The American journal of tropical medicine and hygiene · 2022Article
- The Importance of Screening for Chagas Disease Against the Backdrop of Changing Epidemiology in the USA.Current tropical medicine reports · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Confirmed diagnosis of chronic Chagas disease (CD) requires positive results by two different IgG serology tests. Variable sensitivity has been reported among tests and in different geographic regions. Inadequate specificity presents a particular challenge in low-prevalence settings such as the United States. This study provides a direct comparison of the latest-generation IgG serology assays with four previously assessed FDA-cleared tests. Seven hundred ten blood donor plasma specimens were evaluated by Wiener Lisado and Wiener v.4.0 enzyme-linked immunosorbent assays (ELISAs) and Abbott PRISM Chagas chemiluminescent assay (ChLIA). Sensitivity and specificity were assessed relative to infection status as determined by the original blood donation testing algorithm. All three latest-generation assays demonstrated 100% specificity (95% confidence interval [CI], 98.6 to 100.0). Wiener Lisado, Wiener v.4.0, and Abbott PRISM had sensitivities of 97.1% (95% CI, 95.1 to 98.4), 98.9% (95% CI, 97.4 to 99.6), and 95.5% (95% CI, 93.2 to 97.3), respectively. As with previously evaluated FDA-cleared tests, all three assays had the highest reactivity and sensitivity in samples from donors born in South America and lowest reactivity and sensitivity in specimens from those born in Mexico, with intermediate results in specimens from Central American donors. Wiener v.4.0 had the highest diagnostic sensitivity in all comparisons. Our findings suggest that the latest-generation CD serology tests could improve diagnostic sensitivity without affecting specificity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.